一品红：注射用硫酸艾沙康唑获药品注册证书

Core Viewpoint - The company Yipinhong (300723) has received approval from the National Medical Products Administration for the drug "Injectable Sulfate of Isavuconazole," which is primarily used to treat invasive aspergillosis and mucormycosis infections in adult patients [1] Group 1 - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the newly approved drug [1] - The approval of Injectable Sulfate of Isavuconazole marks a significant milestone for the company in expanding its pharmaceutical product offerings [1] - The drug targets serious fungal infections, indicating a strategic focus on addressing critical healthcare needs [1]